Kevin Kunzmann

Tralokinumab provides both symptom and psychosocial benefit for adolescent patients with moderate to severe 

 over 16 weeks, according to new findings.

In new data derived from the phase 3 ECZTRA clinical trial program for the interleukin 13 (IL-13) inhibitor agent, a team or US investigators reported improved sleep, anxiety and depression, and quality of life associated with the disease among treated adolescents.

The findings further support use of the LEO Pharma drug—recently approved by the US Food and Drug Administration (FDA) for adults with atopic dermatitis—as a comprehensive benefit for adolescents whose psychosocial factors may be heightened due to the chronic skin disease.

Led by Weily Soong, MD, a physician at the AllerVie Health - Alabama Allergy & Asthma Center, investigators evaluated the effect of tralokinumab on patient-reported outcomes in the ECZTRA 6 trial through 16 weeks. Previously, the phase 3 study showed tralokinumab provided “substantial efficacy” and good tolerability in adolescent patients.

Their patient population included 301 adolescents aged 12-17 years old randomized to receive either subcutaneous tralokinumab 150 mg (n = 100), 300 mg (n = 101), or placebo (n = 100) once every 2 weeks. Key patient-reported outcomes included:

Itch per worst pruritus Numeric Rating Scale (NRS)

Sleep interference per eczema-related sleep NRS

Children’s Dermatology Life Quality Index (CDLQI)

Hospital Anxiety and Depression Scale (HADS)

Trial participants who received rescue therapy or had missing data were defined as non-responders.

Investigators observed significantly greater proportions of patients receiving either dose of tralokinumab achieving a ≥4 point improvement in adolescent worst pruritus NRS:

Investigators additionally observed ≥6 point improvements in CDLQI in 31.0% (

 <.001) of the tralokinumab arm, respectively, versus 15.9% of the placebo arm. Another 38.7% (

 <.001) of the tralokinumab treatment arms reported ≥6 point improvement in poem versus 10.5% of the placebo arm.

Similarly to the other outcomes, tralokinumab was associated significant improvements in eczema-related sleep NRS and mean change in HADS versus placebo.

“Tralokinumab significantly improved symptomatic and psychosocial impacts of moderate to severe atopic dermatitis in adolescents using clinically relevant patient-reported outcomes at week 16, including itch, sleep interference, anxiety/depression, and overall quality of life,” they concluded.

The study, “Tralokinumab Treatment Substantially Improves Patient-Reported Outcomes in Adolescents with Moderate-to-Severe Atopic Dermatitis at 16 Weeks,” was published online in 

Originally published on our sister brand, 

Articles

New data from ECZTRA 6 show improved sleep quality, itch relief and quality of life among teenagers treating atopic dermatitis with the IL-13 inhibitor.

Tralokinumab benefits adolescent eczema patient-reported outcomes at 16 weeks

The state of maternal immunization is much different now than from when Gregory M. Glenn, MD, first started in healthcare. It was a widely studied field, but still not as practiced in pregnant women.

Now, Glenn, president of Research & Development for Novavax Inc., and his team of investigators are at the cusp of revolutionary development for maternal 

The Maryland-based clinical-stage vaccine company intends to share data in the following weeks on its first clinical trial of an investigative 

 vaccine in third-trimester pregnant women. Its findings and eventual successive studies could alter the scope of care for RSV, the most common cause of bronchiolitis and pneumonia in children younger than 1 year old in the US.

The trial-which has been ongoing for 4 years and has assessed the potential vaccine in about 3000 treatment-eligible pregnant subjects in that time-has been carried out by teams comprised of RSV, vaccination, and maternity-care specialists across 11 countries. “This is an incredible number of people working on a trial,” Glenn told MD Magazine®. “And because they’re on the front line, they are extremely excited at the prospect of having a vaccine for infants.”

Glenn also noted at least 1 other party’s particular interest in the development of an RSV vaccine: the Bill & Melinda Gates Foundation granted $89 million for the outside costs of the trial in 2015.

If the phase 3 results indicate the Novavax vaccine was capable of reaching its primary endpoint-reduced incidence of medically significant RSV lower respiratory tract infection (LRTI) with either hypoxemia or tachypnea in infants through 90 days of life-and key secondary endpoints, it could eventually become the first US Food and Drug Administration (FDA) approved RSV vaccine indicated for infants.

Investigator Pedro A. Piedra, MD, a professor in the Department of Molecular Virology and Microbiology, and Pediatrics at Baylor College of Medicine, explained to MD Mag that the international focus of the study was for good purpose-RSV is recognized by the World Health Organization (WHO) as causing significant morbidity and mortality risk in children 5 years and younger, with no vaccines available.

“Children most at risk are under 6 months of age,” Piedra said. “But to target them with vaccination becomes very difficult. We often think about giving children vaccines at 2 to 6 months. This leaves the concept of maternal immunization.”

Investigators randomized pregnant women aged 18 to 40 years 2:1 to receive vaccine or placebo, respectively. Though no data pertaining to the vaccine’s efficacy is yet available, investigators have received some indication of its safety and tolerability. Glenn noted that an FDA-approved safety data monitoring board was granted unblinded observation of the trial results.

Since starting the study, the Novavax team received no notification of unsafe events that would require them to suspend or prematurely end the study. Piedra emphasized this observation spanned the entire four-year duration, as that is how long it took the investigators to fulfill patient participation standards.

“One always has to be cautious, but I’m cautiously optimistic that the vaccine will meet its primary outcome,” Piedra said.

Piedra noted alternative therapies for pediatric RSV are limited. Monoclonal antibodies with extended half-life have shown capability to protect infants from maternal birth through early childhood, yet carry a greater market price and risk of safety than a vaccine would. There’s also something to be said for a vaccine’s potential as a widespread, long-term influencer in pediatric pulmonary health.

“It’s important to understand RSV is a global pathogen,” Piedra explained. “The majority of deaths occur in low-resourced countries, but it’s the number 1 cause of hospitalization in children under the age of 1 in US. It’s also associated with increased asthma risk within a patient’s first decade of life.”

It would be interesting, he suggested, to see the both the acute and long-term impacts of a vaccination down the road.

Glenn recalled a time when the majority of infants and young children in the intensive care unit could have been practically split by 2 specialties: gastroenterology, and pulmonary. The former is no longer a driver of pediatric disease; the development of a rotavirus vaccine resolved many issues in the field. He projects a similar outcome for the latter with a capable RSV vaccine.

“From a biotech standpoint, it’s got to be one of the biggest pieces of news this year, just because of the impact,” Glenn said.

Beyond a November 2017 futility analysis allowed by the FDA, Glenn, Piedra and the investigators are not aware of any impeding outcome data. But there’s optimism-due to previous results, interim discussion, and the scale of the trial itself.

“It’s been a long wait,” Glenn said.

Kevin Kunzmann

Articles

Tralokinumab benefits adolescent eczema patient-reported outcomes at 16 weeks

Novavax nears maternal immunization results for RSV vaccine